The triangle of death of neurons: Oxidative damage, mitochondrial dysfunction, and loss of choline-containing biomolecules in brains of mice treated with doxorubicin. Advanced insights into mechanisms of chemotherapy induced cognitive impairment ("chemobrain") involving TNF-α.
Animals
Antibiotics, Antineoplastic
/ pharmacology
Brain
/ drug effects
Choline
/ metabolism
Cognitive Dysfunction
/ chemically induced
Doxorubicin
/ pharmacology
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Mitochondria
/ drug effects
Neurons
/ drug effects
Oxidation-Reduction
Oxidative Stress
/ drug effects
Tumor Necrosis Factor-alpha
/ physiology
Chemotherapy-induced cognitive impairment
Doxorubicin
MRS
Mitochondrial dysfunction
Oxidative stress
Phospholipases
Tumor necrosis factor-alpha
Journal
Free radical biology & medicine
ISSN: 1873-4596
Titre abrégé: Free Radic Biol Med
Pays: United States
ID NLM: 8709159
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
26
11
2018
accepted:
23
12
2018
pubmed:
30
12
2018
medline:
27
3
2020
entrez:
30
12
2018
Statut:
ppublish
Résumé
Cancer treatments are developing fast and the number of cancer survivors could arise to 20 million in United State by 2025. However, a large fraction of cancer survivors demonstrate cognitive dysfunction and associated decreased quality of life both shortly, and often long-term, after chemotherapy treatment. The etiologies of chemotherapy induced cognitive impairment (CICI) are complicated, made more so by the fact that many anti-cancer drugs cannot cross the blood-brain barrier (BBB). Multiple related factors and confounders lead to difficulties in determining the underlying mechanisms. Chemotherapy induced, oxidative stress-mediated tumor necrosis factor-alpha (TNF-α) elevation was considered as one of the main candidate mechanisms underlying CICI. Doxorubicin (Dox) is a prototypical reactive oxygen species (ROS)-generating chemotherapeutic agent used to treat solid tumors and lymphomas as part of multi-drug chemotherapeutic regimens. We previously reported that peripheral Dox-administration leads to plasma protein damage and elevation of TNF-α in plasma and brain of mice. In the present study, we used TNF-α null (TNFKO) mice to investigate the role of TNF-α in Dox-induced, oxidative stress-mediated alterations in brain. We report that Dox-induced oxidative stress in brain is ameliorated and brain mitochondrial function assessed by the Seahorse-determined oxygen consumption rate (OCR) is preserved in brains of TNFKO mice. Further, we show that Dox-decreased the level of hippocampal choline-containing compounds and brain phospholipases activity are partially protected in TNFKO group in MRS study. Our results provide strong evidence that Dox-targeted mitochondrial damage and levels of brain choline-containing metabolites, as well as phospholipases changes decreased in the CNS are associated with oxidative stress mediated by TNF-α. These results are consistent with the notion that oxidative stress and elevated TNF-α in brain underlie the damage to mitochondria and other pathological changes that lead to CICI. The results are discussed with reference to our identifying a potential therapeutic target to protect against cognitive problems after chemotherapy.
Identifiants
pubmed: 30593843
pii: S0891-5849(18)32457-2
doi: 10.1016/j.freeradbiomed.2018.12.029
pmc: PMC6588453
mid: NIHMS1517901
pii:
doi:
Substances chimiques
Antibiotics, Antineoplastic
0
Tumor Necrosis Factor-alpha
0
Doxorubicin
80168379AG
Choline
N91BDP6H0X
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-8Subventions
Organisme : NIGMS NIH HHS
ID : P20 GM121307
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA177558
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA217934
Pays : United States
Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.
Références
J Immunol. 2000 Jul 15;165(2):1013-21
pubmed: 10878378
J Biol Chem. 2000 Mar 31;275(13):9699-708
pubmed: 10734122
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051
Gut. 2002 Mar;50(3):314-21
pubmed: 11839707
Cell Signal. 2008 Dec;20(12):2198-207
pubmed: 18694819
PLoS One. 2014 Jul 21;9(7):e102373
pubmed: 25047119
J Neurochem. 2007 Jan;100(1):191-201
pubmed: 17227439
Eur J Cancer. 1991;27(5):532-5
pubmed: 1647181
Oncotarget. 2018 Jul 13;9(54):30324-30339
pubmed: 30100992
Clin Radiol. 2009 Jan;64(1):12-21
pubmed: 19070693
Sci Rep. 2018 Jul 3;8(1):10006
pubmed: 29968773
Comput Biol Med. 2001 Jul;31(4):269-86
pubmed: 11334636
Cancer Res. 1987 Feb 1;47(3):799-802
pubmed: 3100025
Int Immunopharmacol. 2001 Jul;1(7):1375-84
pubmed: 11460317
Metab Brain Dis. 2008 Sep;23(3):325-33
pubmed: 18690526
Mol Pharmacol. 1977 Sep;13(5):901-10
pubmed: 19695
J Neurosci Res. 2007 Feb 15;85(3):497-503
pubmed: 17171703
Cell Death Differ. 2008 Nov;15(11):1782-93
pubmed: 18636075
Immunol Lett. 2016 Jun;174:9-18
pubmed: 27058440
Neurochem Res. 2016 Sep;41(9):2352-66
pubmed: 27209303
Neuroscience. 2008 Jan 24;151(2):622-9
pubmed: 18160224
Brain Behav Immun. 2013 Mar;30 Suppl:S109-16
pubmed: 22698992
Mol Cancer Ther. 2006 Nov;5(11):2851-60
pubmed: 17121932
Cancer Res. 2006 Apr 15;66(8):4329-38
pubmed: 16618758
Behav Brain Res. 2009 Aug 24;202(1):26-31
pubmed: 19447277
Toxicology. 1999 May 3;134(1):51-62
pubmed: 10413188
Neurol Neurochir Pol. 2003;37(4):783-98
pubmed: 14746239
Free Radic Biol Med. 2014 Sep;74:157-74
pubmed: 24996204
Eur J Biochem. 1993 Mar 1;212(2):491-7
pubmed: 8444187
Adv Drug Deliv Rev. 2009 Apr 28;61(4):290-302
pubmed: 19249331
Biochim Biophys Acta. 2002 Dec 30;1585(2-3):77-86
pubmed: 12531540
Neuroimaging Clin N Am. 2013 Aug;23(3):359-80
pubmed: 23928194
Adv Exp Med Biol. 2010;678:vii-viii
pubmed: 20737998
Mol Interv. 2007 Jun;7(3):147-56
pubmed: 17609521
Free Radic Biol Med. 2011 Jun 1;50(11):1630-8
pubmed: 21421044
Neuroscience. 2010 Jun 2;167(4):969-73
pubmed: 20338225
Antioxid Redox Signal. 2012 Dec 1;17(11):1610-55
pubmed: 22115501
Radiology. 2006 Aug;240(2):318-32
pubmed: 16864664
Free Radic Biol Med. 2006 Nov 1;41(9):1470-7
pubmed: 17023274
Neuroscience. 2010 Mar 31;166(3):796-807
pubmed: 20096337
Chem Phys Lipids. 1999 Apr;98(1-2):153-64
pubmed: 10358937
Behav Brain Res. 2015 Oct 1;292:184-93
pubmed: 26057360
Adv Exp Med Biol. 2010;678:147-56
pubmed: 20738017
Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2652-7
pubmed: 20133798
Gan. 1975 Feb;66(1):43-7
pubmed: 239881
Free Radic Res. 2005 Nov;39(11):1147-54
pubmed: 16298740
Free Radic Biol Med. 2013 Dec;65:324-334
pubmed: 23872023
Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3308-12
pubmed: 8622934
Nat Rev Drug Discov. 2016 Apr;15(4):275-92
pubmed: 26794270
Pharmacol Res. 2017 Mar;117:267-273
pubmed: 28063894
Behav Neurosci. 2013 Oct;127(5):642-54
pubmed: 24128354
J Leukoc Biol. 2005 Jul;78(1):266-78
pubmed: 15817701
Neurobiol Dis. 2006 Jul;23(1):127-39
pubmed: 16697651
J Biol Chem. 2002 Aug 16;277(33):29626-33
pubmed: 12050154
Free Radic Biol Med. 2013 Oct;63:1-29
pubmed: 23567191
J Physiol Pharmacol. 2017 Apr;68(2):295-308
pubmed: 28614779
PLoS One. 2015 Apr 24;10(4):e0124988
pubmed: 25909710